Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model

Fig. 2

Validation of in vitro oncolytic adenoviral replication efficiency and the expression patterns of the encoded TRAIL and IL-12 transgenes in human HCC cells. HuH7 cells were cultured and then treated with PBS, Ad-ΔB, or Ad-ΔB/TRAIL+ Ad-ΔB/IL-12 at a MOI of 5 for each virus. Two days post-treatment, the cell lysates and conditioned media were harvested and relative mRNA and protein levels of TRAIL (a and b), or IL-12 (c and d) were measured by using Q-RT-PCR and ELISA assays, respectively. Data are represented as mean ± SE. In addition, viral production was determined by measuring the expression of Ad E1A protein (e) by western blot assay using rabbit anti-Ad E1A primary antibody

Back to article page